Immune Signaling Research

VIP (Vasoactive Intestinal Peptide)

Not FDA approvedImmune & gut
5.4/10

BioHarmony verdict

Neutral

VIP, or vasoactive intestinal peptide, is the endogenous neuropeptide whose synthetic form is aviptadil, used off-label for anti-inflammatory, immune, respiratory, and erectile purposes. The mechanism and trial volume are real, but the two largest respiratory trials missed their primary endpoints, per Youssef 2022 and TESICO 2023, and the strongest positive randomized result is the niche erectile combination…

Read full report

What is VIP (Vasoactive Intestinal Peptide)?

VIP, short for vasoactive intestinal peptide, is your body's own 28-amino-acid neuropeptide, and its synthetic pharmaceutical form is the drug aviptadil. It scores at Neutral because the mechanism is genuine and the registered-trial footprint is larger than most grey-market peptides, yet the net efficacy record outside one niche use is weak. The honest one-line version: real biology, real trials, modest and indication-specific results.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Agonist at VPAC1 and VPAC2 receptors, raising cyclic AMP to dilate vessels, suppress inflammatory cytokines, and induce regulatory T cells

Safety watch-outs

  • Lightheadedness, fainting, or persistent low blood pressure (hypotension): stop and reassess, since vasodilation is the core mechanism and…
  • Fast or pounding heartbeat (tachycardia or palpitations) that does not settle: reduce dose or stop.
  • Persistent diarrhea or gut cramping that does not settle: reduce dose or stop.
  • Any nasal irritation, reaction, or signs of a non-sterile compounded product: stop and check your source quality.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for VIP (Vasoactive Intestinal Peptide) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (3)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalNot FDA approved
CompoundingFDA lists vasoactive intestinal peptide as a 503A Category 1 bulk substance under evaluation
Last checked2026-07-13
Next review2026-10-11

FDA's current 503A interim-policy list places vasoactive intestinal peptide in Category 1, meaning it remains under evaluation for the bulks list. Category 1 status is not FDA approval of a drug product.

Primary sources

  1. 7.5/10BPC-157Strong recommendRecoveryNot FDA approvedBPC-157 is a 15-amino-acid gastric peptide fragment with consistent preclinical repair data, including a 2025 sports-medicine systematic review of 36 studies with 35…
  2. 7.5/10TB-500 (Thymosin Beta-4 Fragment)Strong recommendRecoveryNot FDA approvedTB-500 is a synthetic LKKTETQ fragment marketed for soft-tissue repair, but most human evidence is on full-length topical thymosin beta-4: Sosne 2023 reported corneal…
  3. 7.4/10GHK-Cu (Copper Peptide)Strong recommendRecoveryNot FDA approvedGHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5%…
  4. 7.3/10Thymosin Alpha-1Strong recommendRecoveryNot FDA approvedFDA identifies immunogenicity and peptide-impurity concerns for compounded thymosin alpha-1 and says available safety information is inadequate.

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.